{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T02:46:55Z","timestamp":1793501215698,"version":"4.5.0"},"reference-count":86,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T00:00:00Z","timestamp":1643846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Epidemiological studies have reported conflicting findings on the potential adverse effects of long-term antihypertensive medication use on cancer risk. Naturally occurring variation in genes encoding antihypertensive drug targets can be used as proxies for these targets to examine the effect of their long-term therapeutic inhibition on disease outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods and findings<\/jats:title>\n                    <jats:p>\n                      We performed a mendelian randomization analysis to examine the association between genetically proxied inhibition of 3 antihypertensive drug targets and risk of 4 common cancers (breast, colorectal, lung, and prostate). Single-nucleotide polymorphisms (SNPs) in\n                      <jats:italic>ACE<\/jats:italic>\n                      ,\n                      <jats:italic>ADRB1<\/jats:italic>\n                      , and\n                      <jats:italic>SLC12A3<\/jats:italic>\n                      associated (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 5.0 \u00d7 10\n                      <jats:sup>\u22128<\/jats:sup>\n                      ) with systolic blood pressure (SBP) in genome-wide association studies (GWAS) were used to proxy inhibition of angiotensin-converting enzyme (ACE), \u03b2-1 adrenergic receptor (ADRB1), and sodium-chloride symporter (NCC), respectively. Summary genetic association estimates for these SNPs were obtained from GWAS consortia for the following cancers: breast (122,977 cases, 105,974 controls), colorectal (58,221 cases, 67,694 controls), lung (29,266 cases, 56,450 controls), and prostate (79,148 cases, 61,106 controls). Replication analyses were performed in the FinnGen consortium (1,573 colorectal cancer cases, 120,006 controls). Cancer GWAS and FinnGen consortia data were restricted to individuals of European ancestry. Inverse-variance weighted random-effects models were used to examine associations between genetically proxied inhibition of these drug targets and risk of cancer. Multivariable mendelian randomization and colocalization analyses were employed to examine robustness of findings to violations of mendelian randomization assumptions. Genetically proxied ACE inhibition equivalent to a 1-mm Hg reduction in SBP was associated with increased odds of colorectal cancer (odds ratio (OR) 1.13, 95% CI 1.06 to 1.22;\n                      <jats:italic>P<\/jats:italic>\n                      = 3.6 \u00d7 10\n                      <jats:sup>\u22124<\/jats:sup>\n                      ). This finding was replicated in the FinnGen consortium (OR 1.40, 95% CI 1.02 to 1.92;\n                      <jats:italic>P<\/jats:italic>\n                      = 0.035). There was little evidence of association of genetically proxied ACE inhibition with risk of breast cancer (OR 0.98, 95% CI 0.94 to 1.02,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.35), lung cancer (OR 1.01, 95% CI 0.92 to 1.10;\n                      <jats:italic>P<\/jats:italic>\n                      = 0.93), or prostate cancer (OR 1.06, 95% CI 0.99 to 1.13;\n                      <jats:italic>P<\/jats:italic>\n                      = 0.08). Genetically proxied inhibition of ADRB1 and NCC were not associated with risk of these cancers. The primary limitations of this analysis include the modest statistical power for analyses of drug targets in relation to some less common histological subtypes of cancers examined and the restriction of the majority of analyses to participants of European ancestry.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this study, we observed that genetically proxied long-term ACE inhibition was associated with an increased risk of colorectal cancer, warranting comprehensive evaluation of the safety profiles of ACE inhibitors in clinical trials with adequate follow-up. There was little evidence to support associations across other drug target\u2013cancer risk analyses, consistent with findings from short-term randomized controlled trials for these medications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pmed.1003897","type":"journal-article","created":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T13:36:10Z","timestamp":1643895370000},"page":"e1003897","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":73,"title":["Genetically proxied therapeutic inhibition of antihypertensive drug targets and risk of common cancers: A mendelian randomization analysis"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4371-0873","authenticated-orcid":true,"given":"James","family":"Yarmolinsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0163-9872","authenticated-orcid":true,"given":"Virginia","family":"D\u00edez-Obrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7918-2040","authenticated-orcid":true,"given":"Tom G.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2984-8366","authenticated-orcid":true,"given":"Marie","family":"Pigeyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Sjaarda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6795-4760","authenticated-orcid":true,"given":"Guillaume","family":"Par\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5064-446X","authenticated-orcid":true,"given":"Venexia M.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8917-7384","authenticated-orcid":true,"given":"Emma E.","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7938-127X","authenticated-orcid":true,"given":"Vanessa Y.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4646-3513","authenticated-orcid":true,"given":"Mireia","family":"Ob\u00f3n-Santacana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Demetrius","family":"Albanes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2421-6127","authenticated-orcid":true,"given":"Jochen","family":"Hampe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9795-1528","authenticated-orcid":true,"given":"Andrea","family":"Gsur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Hampel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2692-221X","authenticated-orcid":true,"given":"Rish K.","family":"Pai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8964-6160","authenticated-orcid":true,"given":"Mark","family":"Jenkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Gallinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1584-5551","authenticated-orcid":true,"given":"Graham","family":"Casey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1226-070X","authenticated-orcid":true,"given":"Wei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8540-7023","authenticated-orcid":true,"given":"Christopher I.","family":"Amos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the International Lung Cancer Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the PRACTICAL consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the MEGASTROKE consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1407-8314","authenticated-orcid":true,"given":"George Davey","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7992-7719","authenticated-orcid":true,"given":"Richard M.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2818-5487","authenticated-orcid":true,"given":"Victor","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,2,3]]},"reference":[{"issue":"10","key":"pmed.1003897.ref001","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1111\/bcp.13692","article-title":"Maitland-van der Zee AH. Prescription patterns of angiotensin-converting enzyme inhibitors for various indications: A UK population-based study","volume":"84","author":"SH Mahmoudpour","year":"2018","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"pmed.1003897.ref002","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(10)70260-6","article-title":"Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324 168 participants from randomised trials","volume":"12","author":"S Bangalore","year":"2011","journal-title":"Lancet Oncol"},{"issue":"4","key":"pmed.1003897.ref003","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/HJH.0b013e328344a7de","article-title":"Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals","volume":"29","year":"2011","journal-title":"J Hypertens"},{"key":"pmed.1003897.ref004","article-title":"Antihypertensive Drugs and Risk of Cancer. Between Scylla and Charybdis","author":"E Sanidas","year":"2020","journal-title":"Am J Hypertens"},{"issue":"4","key":"pmed.1003897.ref005","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1002\/jcp.22848","article-title":"Targeting of substance P induces cancer cell death and decreases the steady state of EGFR and Her2","volume":"227","author":"C Mayordomo","year":"2012","journal-title":"J Cell Physiol"},{"issue":"7","key":"pmed.1003897.ref006","first-page":"881","article-title":"Cancer progression and substance P","volume":"29","author":"R Cove\u00f1as","year":"2014","journal-title":"Histol Histopathol"},{"issue":"1","key":"pmed.1003897.ref007","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1365-2125.2012.04170.x","article-title":"Long term use of drugs affecting the renin-angiotensin system and the risk of cancer: a population-based case-control study","volume":"74","author":"J Hallas","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"pmed.1003897.ref008","doi-asserted-by":"crossref","first-page":"k4209","DOI":"10.1136\/bmj.k4209","article-title":"Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study","volume":"363","author":"BM Hicks","year":"2018","journal-title":"BMJ"},{"issue":"10","key":"pmed.1003897.ref009","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1007\/s10552-011-9819-3","article-title":"The association between antihypertensive drug use and incidence of prostate cancer in Finland: a population-based case-control study","volume":"22","author":"KJ Kemppainen","year":"2011","journal-title":"Cancer Causes Control"},{"issue":"3","key":"pmed.1003897.ref010","article-title":"Association between Angiotensin-Converting Enzyme Inhibitors and Lung Cancer-A Nationwide, Population-Based, Propensity Score-Matched Cohort Study","volume":"12","author":"SY Lin","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"1","key":"pmed.1003897.ref011","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s10549-015-3311-9","article-title":"Antihypertensive medication use and incident breast cancer in women","volume":"150","author":"EE Devore","year":"2015","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"pmed.1003897.ref012","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/pros.10294","article-title":"Association between captopril, other antihypertensive drugs and risk of prostate cancer","volume":"58","author":"G Ronquist","year":"2004","journal-title":"Prostate"},{"issue":"11","key":"pmed.1003897.ref013","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1158\/1055-9965.EPI-08-0095","article-title":"Cardiovascular medication use and risk for colorectal cancer","volume":"17","author":"DM Boudreau","year":"2008","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"3","key":"pmed.1003897.ref014","doi-asserted-by":"crossref","first-page":"1470320319895646","DOI":"10.1177\/1470320319895646","article-title":"Renin-angiotensin system inhibitor use and colorectal cancer risk and mortality: A dose-response meta analysis","volume":"21","author":"X Chen","year":"2020","journal-title":"J Renin-Angiotensin-Aldosterone Syst"},{"issue":"3","key":"pmed.1003897.ref015","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1161\/HYPERTENSIONAHA.120.15317","article-title":"ACE (Angiotensin-Converting Enzyme) Inhibitors\/Angiotensin Receptor Blockers Are Associated With Lower Colorectal Cancer Risk: A Territory-Wide Study With Propensity Score Analysis","volume":"76","author":"KS Cheung","year":"2020","journal-title":"Hypertension"},{"issue":"7","key":"pmed.1003897.ref016","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/pds.883","article-title":"Approaches to combat with confounding by indication in observational studies of intended drug effects","volume":"12","author":"AD McMahon","year":"2003","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"pmed.1003897.ref017","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1097\/MCG.0b013e3181ea1044","article-title":"Long-term use of angiotensin converting enzyme inhibitors is associated with decreased incidence of advanced adenomatous colon polyps","volume":"45","author":"R Kedika","year":"2011","journal-title":"J Clin Gastroenterol"},{"issue":"1","key":"pmed.1003897.ref018","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/bjc.2013.292","article-title":"The impact of aspirin, statins and ACE-inhibitors on the presentation of colorectal neoplasia in a colorectal cancer screening programme","volume":"109","author":"D Mansouri","year":"2013","journal-title":"Br J Cancer"},{"issue":"9","key":"pmed.1003897.ref019","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/aje\/kwg231","article-title":"Evaluating medication effects outside of clinical trials: new-user designs","volume":"158","author":"WA Ray","year":"2003","journal-title":"Am J Epidemiol"},{"issue":"9123","key":"pmed.1003897.ref020","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0140-6736(98)03228-0","article-title":"Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?","volume":"352","author":"AF Lever","year":"1998","journal-title":"Lancet"},{"issue":"12","key":"pmed.1003897.ref021","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.2337\/dc12-0788","article-title":"Metformin and the risk of cancer: time-related biases in observational studies","volume":"35","author":"S Suissa","year":"2012","journal-title":"Diabetes Care"},{"issue":"6","key":"pmed.1003897.ref022","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1023\/B:CACO.0000036152.58271.5e","article-title":"Antihypertensive drug use and the risk of prostate cancer (Canada)","volume":"15","author":"L Perron","year":"2004","journal-title":"Cancer Causes Control"},{"issue":"10","key":"pmed.1003897.ref023","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/sj.jhh.1002075","article-title":"Hypertension, diuretics and breast cancer risk","volume":"20","author":"JA Largent","year":"2006","journal-title":"J Hum Hypertens"},{"issue":"16","key":"pmed.1003897.ref024","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1002\/cncr.26727","article-title":"Beta blocker use and colorectal cancer risk: population-based case-control study","volume":"118","author":"L Jansen","year":"2012","journal-title":"Cancer"},{"issue":"17","key":"pmed.1003897.ref025","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1001\/jamainternmed.2013.9071","article-title":"Use of antihypertensive medications and breast cancer risk among women aged 55 to 74 years","volume":"173","author":"CI Li","year":"2013","journal-title":"JAMA Intern Med"},{"issue":"12","key":"pmed.1003897.ref026","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/S0895-7061(98)00176-9","article-title":"Calcium channel blocker use and the risk of prostate cancer","volume":"11","author":"RM Vezina","year":"1998","journal-title":"Am J Hypertens"},{"issue":"8","key":"pmed.1003897.ref027","doi-asserted-by":"crossref","first-page":"e0159672","DOI":"10.1371\/journal.pone.0159672","article-title":"The Use of Antihypertensive Medication and the Risk of Breast Cancer in a Case-Control Study in a Spanish Population: The MCC-Spain Study","volume":"11","author":"I G\u00f3mez-Acebo","year":"2016","journal-title":"PLoS ONE"},{"issue":"2","key":"pmed.1003897.ref028","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0002-9343(00)00674-4","article-title":"Is diuretic therapy associated with an increased risk of colon cancer?","volume":"110","author":"A Tenenbaum","year":"2001","journal-title":"Am J Med"},{"key":"pmed.1003897.ref029","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ijcard.2015.02.015","article-title":"Carvedilol use is associated with reduced cancer risk: A nationwide population-based cohort study","volume":"184","author":"CS Lin","year":"2015","journal-title":"Int J Cardiol"},{"issue":"4","key":"pmed.1003897.ref030","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1185\/03007995.2013.772505","article-title":"Further data on beta-blockers and cancer risk: observational study and meta-analysis of randomized clinical trials","volume":"29","author":"M Monami","year":"2013","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"pmed.1003897.ref031","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ije\/dyg070","article-title":"\u2019Mendelian randomization\u2019: can genetic epidemiology contribute to understanding environmental determinants of disease?","volume":"32","author":"GD Smith","year":"2003","journal-title":"Int J Epidemiol"},{"issue":"9","key":"pmed.1003897.ref032","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1158\/1055-9965.EPI-17-1177","article-title":"Causal Inference in Cancer Epidemiology: What Is the Role of Mendelian Randomization?","volume":"27","author":"J Yarmolinsky","year":"2018","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"15","key":"pmed.1003897.ref033","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.jacc.2015.02.020","article-title":"Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 \u00d7 2 factorial Mendelian randomization study","volume":"65","author":"BA Ference","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"pmed.1003897.ref034","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1056\/NEJMoa1604304","article-title":"Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes","volume":"375","author":"BA Ference","year":"2016","journal-title":"N Engl J Med"},{"issue":"8","key":"pmed.1003897.ref035","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nrd4051","article-title":"Validating therapeutic targets through human genetics","volume":"12","author":"RM Plenge","year":"2013","journal-title":"Nat Rev Drug Discov"},{"issue":"9965","key":"pmed.1003897.ref036","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0140-6736(14)61183-1","article-title":"HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials","volume":"385","author":"DI Swerdlow","year":"2015","journal-title":"Lancet"},{"issue":"7678","key":"pmed.1003897.ref037","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/nature24284","article-title":"Association analysis identifies 65 new breast cancer risk loci","volume":"551","author":"K Michailidou","year":"2017","journal-title":"Nature"},{"issue":"1","key":"pmed.1003897.ref038","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41588-018-0286-6","article-title":"Discovery of common and rare genetic risk variants for colorectal cancer","volume":"51","author":"JR Huyghe","year":"2019","journal-title":"Nat Genet"},{"issue":"7","key":"pmed.1003897.ref039","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/ng.3892","article-title":"Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes","volume":"49","author":"JD McKay","year":"2017","journal-title":"Nat Genet"},{"issue":"7","key":"pmed.1003897.ref040","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/s41588-018-0142-8","article-title":"Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci","volume":"50","author":"FR Schumacher","year":"2018","journal-title":"Nat Genet"},{"issue":"2","key":"pmed.1003897.ref041","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1158\/1055-9965.EPI-19-0755","article-title":"Identification of Novel Loci and New Risk Variant in Known Loci for Colorectal Cancer Risk in East Asians","volume":"29","author":"Y Lu","year":"2020","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"17","key":"pmed.1003897.ref042","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1093\/bioinformatics\/btq340","article-title":"METAL: fast and efficient meta-analysis of genomewide association scans","volume":"26","author":"CJ Willer","year":"2010","journal-title":"Bioinformatics"},{"issue":"10","key":"pmed.1003897.ref043","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1038\/s41588-018-0205-x","article-title":"Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits","volume":"50","author":"E Evangelou","year":"2018","journal-title":"Nat Genet"},{"issue":"1","key":"pmed.1003897.ref044","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/ng.3715","article-title":"Genome-wide association analyses using electronic health records identify new loci influencing blood pressure variation","volume":"49","author":"TJ Hoffmann","year":"2017","journal-title":"Nat Genet"},{"issue":"4","key":"pmed.1003897.ref045","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/aje\/kwu283","article-title":"Multivariable Mendelian Randomization: The Use of Pleiotropic Genetic Variants to Estimate Causal Effects","volume":"181","author":"S Burgess","year":"2015","journal-title":"Am J Epidemiol"},{"issue":"4","key":"pmed.1003897.ref046","doi-asserted-by":"crossref","first-page":"835","DOI":"10.2337\/dc19-1973","article-title":"ACE and Type 2 Diabetes Risk: A Mendelian Randomization Study","volume":"43","author":"M Pigeyre","year":"2020","journal-title":"Diabetes Care"},{"issue":"4","key":"pmed.1003897.ref047","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41588-018-0058-3","article-title":"Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes","volume":"50","author":"R Malik","year":"2018","journal-title":"Nat Genet"},{"issue":"11","key":"pmed.1003897.ref048","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1038\/s41588-018-0241-6","article-title":"Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps","volume":"50","author":"A Mahajan","year":"2018","journal-title":"Nat Genet"},{"issue":"4","key":"pmed.1003897.ref049","first-page":"Cd001841","article-title":"First-line drugs for hypertension","volume":"4","author":"JM Wright","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"pmed.1003897.ref050","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/tpj.2009.70","article-title":"A genome-wide association study identifies new loci for ACE activity: potential implications for response to ACE inhibitor","volume":"10","author":"CM Chung","year":"2010","journal-title":"Pharmacogenomics J"},{"issue":"3","key":"pmed.1003897.ref051","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s41588-018-0047-6","article-title":"Genetic analysis of quantitative traits in the Japanese population links cell types to complex human diseases","volume":"50","author":"M Kanai","year":"2018","journal-title":"Nat Genet"},{"issue":"11","key":"pmed.1003897.ref052","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1002\/sim.7221","article-title":"A framework for the investigation of pleiotropy in two-sample summary data Mendelian randomization","volume":"36","author":"J Bowden","year":"2017","journal-title":"Stat Med"},{"issue":"7571","key":"pmed.1003897.ref053","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nature15393","article-title":"A global reference for human genetic variation","volume":"526","author":"A Auton","year":"2015","journal-title":"Nature"},{"issue":"8","key":"pmed.1003897.ref054","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/gepi.22077","article-title":"Mendelian randomization with fine-mapped genetic data: Choosing from large numbers of correlated instrumental variables","volume":"41","author":"S Burgess","year":"2017","journal-title":"Genet Epidemiol"},{"issue":"3","key":"pmed.1003897.ref055","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/ije\/dyr036","article-title":"Avoiding bias from weak instruments in Mendelian randomization studies","volume":"40","author":"S Burgess","year":"2011","journal-title":"Int J Epidemiol"},{"issue":"8","key":"pmed.1003897.ref056","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/gepi.21765","article-title":"Statistical testing of shared genetic control for potentially related traits","volume":"37","author":"C. Wallace","year":"2013","journal-title":"Genet Epidemiol"},{"issue":"5","key":"pmed.1003897.ref057","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1053\/j.gastro.2019.12.020","article-title":"Circulating Levels of Insulin-like Growth Factor 1 and Insulin-like Growth Factor Binding Protein 3 Associate With Risk of Colorectal Cancer Based on Serologic and Mendelian Randomization Analyses","volume":"158","author":"N Murphy","year":"2020","journal-title":"Gastroenterology"},{"issue":"3","key":"pmed.1003897.ref058","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1093\/ije\/dyz151","article-title":"Commentary: What can Mendelian randomization tell us about causes of cancer?","volume":"48","author":"D Mariosa","year":"2019","journal-title":"Int J Epidemiol"},{"key":"pmed.1003897.ref059","article-title":"Mendelian randomization analyses suggest a role for cholesterol in the development of endometrial cancer","author":"PF Kho","year":"2020","journal-title":"Int J Cancer"},{"issue":"1","key":"pmed.1003897.ref060","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S2468-1253(19)30294-8","article-title":"Modifiable pathways for colorectal cancer: a mendelian randomisation analysis","volume":"5","author":"AJ Cornish","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"pmed.1003897.ref061","doi-asserted-by":"crossref","first-page":"11008","DOI":"10.1038\/s41598-017-10812-1","article-title":"Genome-wide analysis of health-related biomarkers in the UK Household Longitudinal Study reveals novel associations","volume":"7","author":"BP Prins","year":"2017","journal-title":"Sci Rep"},{"key":"pmed.1003897.ref062","doi-asserted-by":"crossref","first-page":"11122","DOI":"10.1038\/ncomms11122","article-title":"Genome-wide study for circulating metabolites identifies 62 loci and reveals novel systemic effects of LPA","volume":"7","author":"J Kettunen","year":"2016","journal-title":"Nat Commun"},{"key":"pmed.1003897.ref063","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.1038\/ncomms5926","article-title":"Novel loci affecting iron homeostasis and their effects in individuals at risk for hemochromatosis","volume":"5","author":"B Benyamin","year":"2014","journal-title":"Nat Commun"},{"issue":"1","key":"pmed.1003897.ref064","doi-asserted-by":"crossref","first-page":"5257","DOI":"10.1038\/s41467-018-07743-4","article-title":"GWAS identifies 14 loci for device-measured physical activity and sleep duration","volume":"9","author":"A Doherty","year":"2018","journal-title":"Nat Commun"},{"issue":"2","key":"pmed.1003897.ref065","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/s41588-018-0307-5","article-title":"Association studies of up to 1.2 million individuals yield new insights into the genetic etiology of tobacco and alcohol use","volume":"51","author":"M Liu","year":"2019","journal-title":"Nat Genet"},{"key":"pmed.1003897.ref066","article-title":"Genetic effects on transcriptome profiles in colon epithelium provide functional insights for genetic risk loci","author":"V D\u00edez-Obrero","year":"2021","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"pmed.1003897.ref067","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13742-015-0047-8","article-title":"Second-generation PLINK: rising to the challenge of larger and richer datasets","volume":"4","author":"CC Chang","year":"2015","journal-title":"Gigascience"},{"issue":"16","key":"pmed.1003897.ref068","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1001\/jama.2021.18236","article-title":"Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement","volume":"326","author":"VW Skrivankova","year":"2021","journal-title":"JAMA"},{"issue":"4","key":"pmed.1003897.ref069","first-page":"Cd003823","article-title":"Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension","volume":"2008","author":"BS Heran","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"pmed.1003897.ref070","doi-asserted-by":"crossref","first-page":"R205","DOI":"10.1152\/ajpregu.00544.2012","article-title":"Angiotensin-converting enzyme and the tumor microenvironment: mechanisms beyond angiogenesis","volume":"305","author":"D Okwan-Duodu","year":"2013","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"5","key":"pmed.1003897.ref071","doi-asserted-by":"crossref","first-page":"H2099","DOI":"10.1152\/ajpheart.00592.2004","article-title":"N-acetyl-seryl-aspartyl-lysyl-proline stimulates angiogenesis in vitro and in vivo","volume":"287","author":"D Wang","year":"2004","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"6220","key":"pmed.1003897.ref072","doi-asserted-by":"crossref","first-page":"1260419","DOI":"10.1126\/science.1260419","article-title":"Proteomics. Tissue-based map of the human proteome","volume":"347","author":"M Uhl\u00e9n","year":"2015","journal-title":"Science"},{"issue":"1","key":"pmed.1003897.ref073","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1038\/s41467-019-09775-w","article-title":"Association analyses identify 31 new risk loci for colorectal cancer susceptibility","volume":"10","author":"PJ Law","year":"2019","journal-title":"Nat Commun"},{"issue":"1","key":"pmed.1003897.ref074","first-page":"19","article-title":"Genetic alterations in colorectal cancer","volume":"5","author":"T Armaghany","year":"2012","journal-title":"Gastrointest Cancer Res"},{"issue":"8","key":"pmed.1003897.ref075","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1080\/17474124.2017.1330150","article-title":"New insights into the earliest stages of colorectal tumorigenesis","volume":"11","author":"CK Sievers","year":"2017","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"9754","key":"pmed.1003897.ref076","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(10)61543-7","article-title":"Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials","volume":"376","author":"PM Rothwell","year":"2010","journal-title":"Lancet"},{"issue":"1","key":"pmed.1003897.ref077","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/epirev\/mxx004","article-title":"Early Life Exposures and Adult Cancer Risk","volume":"39","author":"MA Clarke","year":"2017","journal-title":"Epidemiol Rev"},{"issue":"4","key":"pmed.1003897.ref078","doi-asserted-by":"crossref","first-page":"e353","DOI":"10.1212\/WNL.0000000000009814","article-title":"Genetically determined blood pressure, antihypertensive drug classes, and risk of stroke subtypes","volume":"95","author":"MK Georgakis","year":"2020","journal-title":"Neurology"},{"issue":"4","key":"pmed.1003897.ref079","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1161\/CIRCULATIONAHA.118.038814","article-title":"Use of Genetic Variants Related to Antihypertensive Drugs to Inform on Efficacy and Side Effects","volume":"140","author":"D Gill","year":"2019","journal-title":"Circulation"},{"issue":"1","key":"pmed.1003897.ref080","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1038\/s41467-019-09572-5","article-title":"Genome-wide association study of medication-use and associated disease in the UK Biobank","volume":"10","author":"Y Wu","year":"2019","journal-title":"Nat Commun"},{"issue":"5","key":"pmed.1003897.ref081","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1517\/13543784.2016.1164141","article-title":"Immunological and pleiotropic effects of individual \u03b2-blockers and their relevance in cancer therapies","volume":"25","author":"JF Chung","year":"2016","journal-title":"Expert Opin Investig Drugs"},{"issue":"12","key":"pmed.1003897.ref082","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/jamaoncol.2019.2996","article-title":"Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study","volume":"5","author":"C Fitzmaurice","year":"2019","journal-title":"JAMA Oncol"},{"issue":"suppl_E","key":"pmed.1003897.ref083","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/eurheartj\/18.suppl_E.14","article-title":"From kinetics to dynamics: Are there differences between ACE inhibitors?","volume":"18","author":"JL Reid","year":"1997","journal-title":"Eur Heart J"},{"issue":"14","key":"pmed.1003897.ref084","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1161\/01.CIR.97.14.1411","article-title":"Angiotensin-converting enzyme inhibitors","volume":"97","author":"NJ Brown","year":"1998","journal-title":"Circulation"},{"issue":"4","key":"pmed.1003897.ref085","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3810\/pgm.2013.07.2687","article-title":"Not all angiotensin-converting enzyme inhibitors are equal: focus on ramipril and perindopril","volume":"125","author":"JJ Dinicolantonio","year":"2013","journal-title":"Postgrad Med"},{"issue":"6","key":"pmed.1003897.ref086","first-page":"1866","article-title":"Triangulation in aetiological epidemiology","volume":"45","author":"DA Lawlor","year":"2016","journal-title":"Int J Epidemiol"}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1003897","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T13:37:42Z","timestamp":1643895462000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1003897"}},"subtitle":[],"editor":[{"given":"Cosetta","family":"Minelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,2,3]]},"references-count":86,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1003897","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.03.11.21252971","asserted-by":"object"}]},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,3]]}}}